{
  "question": "Gp2b3A inhibitors are all except -",
  "is_multi_choice": true,
  "correct_answer": "opd",
  "options": {
    "opa": "Abciximab",
    "opb": "Eptifibatide",
    "opc": "Tirofiban",
    "opd": "Prasugrel"
  },
  "topic_name": "Pharmacology",
  "context": null,
  "initial_causal_graph": {
    "nodes": [],
    "relationships": [],
    "paths": []
  },
  "causal_graph": {
    "nodes": [],
    "relationships": [],
    "paths": []
  },
  "knowledge_graph": {
    "nodes": [
      [
        "abciximab",
        "Anticoagulants",
        "Pharmaceutical Preparations",
        "prasugrel"
      ],
      [
        "abciximab",
        "Complication",
        "Alleles",
        "prasugrel"
      ],
      [
        "eptifibatide",
        "Complication",
        "Alleles",
        "prasugrel"
      ],
      [
        "eptifibatide",
        "Abnormal renal function",
        "Alleles",
        "prasugrel"
      ],
      [
        "tirofiban",
        "Pharmaceutical Preparations",
        "prasugrel"
      ],
      [
        "Antiplatelet Agents",
        "Pharmaceutical Preparations",
        "prasugrel"
      ],
      [
        "Antiplatelet Agents",
        "Pharmaceutical Preparations",
        "prasugrel"
      ],
      [
        "abciximab",
        "Anticoagulants",
        "Pharmaceutical Preparations",
        "prasugrel"
      ],
      [
        "abciximab",
        "Complication",
        "Alleles",
        "prasugrel"
      ],
      [
        "eptifibatide",
        "Complication",
        "Alleles",
        "prasugrel"
      ],
      [
        "eptifibatide",
        "Abnormal renal function",
        "Alleles",
        "prasugrel"
      ],
      [
        "tirofiban",
        "Pharmaceutical Preparations",
        "prasugrel"
      ],
      [
        "Pharmaceutical Preparations",
        "Complication",
        "abciximab"
      ],
      [
        "Pharmaceutical Preparations",
        "Complication",
        "abciximab"
      ],
      [
        "abciximab",
        "Anticoagulants",
        "Pharmaceutical Preparations",
        "prasugrel"
      ],
      [
        "abciximab",
        "Complication",
        "Alleles",
        "prasugrel"
      ],
      [
        "eptifibatide",
        "Complication",
        "Alleles",
        "prasugrel"
      ],
      [
        "eptifibatide",
        "Abnormal renal function",
        "Alleles",
        "prasugrel"
      ],
      [
        "tirofiban",
        "Pharmaceutical Preparations",
        "prasugrel"
      ],
      [
        "thienopyridine",
        "Thrombosis",
        "HPR gene|HPR",
        "prasugrel"
      ],
      [
        "thienopyridine",
        "Thrombosis",
        "CYP2C19 gene|CYP2C19",
        "prasugrel"
      ]
    ],
    "relationships": [
      [
        "INTERACTS_WITH",
        "INTERACTS_WITH",
        "INTERACTS_WITH"
      ],
      [
        "TREATS",
        "ASSOCIATED_WITH",
        "INTERACTS_WITH"
      ],
      [
        "PREDISPOSES",
        "ASSOCIATED_WITH",
        "INTERACTS_WITH"
      ],
      [
        "TREATS",
        "ASSOCIATED_WITH",
        "INTERACTS_WITH"
      ],
      [
        "ISA",
        "INTERACTS_WITH"
      ],
      [
        "ISA",
        "INTERACTS_WITH"
      ],
      [
        "INTERACTS_WITH",
        "INTERACTS_WITH"
      ],
      [
        "INTERACTS_WITH",
        "INTERACTS_WITH",
        "INTERACTS_WITH"
      ],
      [
        "TREATS",
        "ASSOCIATED_WITH",
        "INTERACTS_WITH"
      ],
      [
        "PREDISPOSES",
        "ASSOCIATED_WITH",
        "INTERACTS_WITH"
      ],
      [
        "TREATS",
        "ASSOCIATED_WITH",
        "INTERACTS_WITH"
      ],
      [
        "ISA",
        "INTERACTS_WITH"
      ],
      [
        "CAUSES",
        "ASSOCIATED_WITH"
      ],
      [
        "TREATS",
        "ASSOCIATED_WITH"
      ],
      [
        "INTERACTS_WITH",
        "INTERACTS_WITH",
        "INTERACTS_WITH"
      ],
      [
        "TREATS",
        "ASSOCIATED_WITH",
        "INTERACTS_WITH"
      ],
      [
        "PREDISPOSES",
        "ASSOCIATED_WITH",
        "INTERACTS_WITH"
      ],
      [
        "TREATS",
        "ASSOCIATED_WITH",
        "INTERACTS_WITH"
      ],
      [
        "ISA",
        "INTERACTS_WITH"
      ],
      [
        "TREATS",
        "ASSOCIATED_WITH",
        "INTERACTS_WITH"
      ],
      [
        "TREATS",
        "ASSOCIATED_WITH",
        "INTERACTS_WITH"
      ]
    ],
    "paths": [
      "(abciximab)-INTERACTS_WITH->(Anticoagulants)-INTERACTS_WITH->(Pharmaceutical Preparations)-INTERACTS_WITH->(prasugrel)",
      "(abciximab)-TREATS->(Complication)-ASSOCIATED_WITH->(Alleles)-INTERACTS_WITH->(prasugrel)",
      "(eptifibatide)-PREDISPOSES->(Complication)-ASSOCIATED_WITH->(Alleles)-INTERACTS_WITH->(prasugrel)",
      "(eptifibatide)-TREATS->(Abnormal renal function)-ASSOCIATED_WITH->(Alleles)-INTERACTS_WITH->(prasugrel)",
      "(tirofiban)-ISA->(Pharmaceutical Preparations)-INTERACTS_WITH->(prasugrel)",
      "(Antiplatelet Agents)-ISA->(Pharmaceutical Preparations)-INTERACTS_WITH->(prasugrel)",
      "(Antiplatelet Agents)-INTERACTS_WITH->(Pharmaceutical Preparations)-INTERACTS_WITH->(prasugrel)",
      "(abciximab)-INTERACTS_WITH->(Anticoagulants)-INTERACTS_WITH->(Pharmaceutical Preparations)-INTERACTS_WITH->(prasugrel)",
      "(abciximab)-TREATS->(Complication)-ASSOCIATED_WITH->(Alleles)-INTERACTS_WITH->(prasugrel)",
      "(eptifibatide)-PREDISPOSES->(Complication)-ASSOCIATED_WITH->(Alleles)-INTERACTS_WITH->(prasugrel)",
      "(eptifibatide)-TREATS->(Abnormal renal function)-ASSOCIATED_WITH->(Alleles)-INTERACTS_WITH->(prasugrel)",
      "(tirofiban)-ISA->(Pharmaceutical Preparations)-INTERACTS_WITH->(prasugrel)",
      "(Pharmaceutical Preparations)-CAUSES->(Complication)-ASSOCIATED_WITH->(abciximab)",
      "(Pharmaceutical Preparations)-TREATS->(Complication)-ASSOCIATED_WITH->(abciximab)",
      "(abciximab)-INTERACTS_WITH->(Anticoagulants)-INTERACTS_WITH->(Pharmaceutical Preparations)-INTERACTS_WITH->(prasugrel)",
      "(abciximab)-TREATS->(Complication)-ASSOCIATED_WITH->(Alleles)-INTERACTS_WITH->(prasugrel)",
      "(eptifibatide)-PREDISPOSES->(Complication)-ASSOCIATED_WITH->(Alleles)-INTERACTS_WITH->(prasugrel)",
      "(eptifibatide)-TREATS->(Abnormal renal function)-ASSOCIATED_WITH->(Alleles)-INTERACTS_WITH->(prasugrel)",
      "(tirofiban)-ISA->(Pharmaceutical Preparations)-INTERACTS_WITH->(prasugrel)",
      "(thienopyridine)-TREATS->(Thrombosis)-ASSOCIATED_WITH->(HPR gene|HPR)-INTERACTS_WITH->(prasugrel)",
      "(thienopyridine)-TREATS->(Thrombosis)-ASSOCIATED_WITH->(CYP2C19 gene|CYP2C19)-INTERACTS_WITH->(prasugrel)"
    ]
  },
  "enhanced_graph": {
    "nodes": [],
    "relationships": [],
    "paths": [
      "(abciximab)-INTERACTS_WITH->(Anticoagulants)-INTERACTS_WITH->(Pharmaceutical Preparations)-INTERACTS_WITH->(prasugrel)",
      "(abciximab)-TREATS->(Complication)-ASSOCIATED_WITH->(Alleles)-INTERACTS_WITH->(prasugrel)",
      "(thienopyridine)-TREATS->(Thrombosis)-ASSOCIATED_WITH->(HPR gene|HPR)-INTERACTS_WITH->(prasugrel)",
      "(eptifibatide)-PREDISPOSES->(Complication)-ASSOCIATED_WITH->(Alleles)-INTERACTS_WITH->(prasugrel)",
      "(eptifibatide)-TREATS->(Abnormal renal function)-ASSOCIATED_WITH->(Alleles)-INTERACTS_WITH->(prasugrel)"
    ]
  },
  "reasoning_chain": [
    "CHAIN: \"Gp2b3A inhibitors\" -> \"include abciximab, eptifibatide, and tirofiban\" -> \"prasugrel is an antiplatelet agent\" -> \"prasugrel is not a Gp2b3A inhibitor\" -> 95%",
    "CHAIN: \"Gp2b3A inhibitors\" -> \"are used to prevent platelet aggregation\" -> \"abciximab, eptifibatide, and tirofiban are examples\" -> \"prasugrel functions differently\" -> \"prasugrel is not classified as a Gp2b3A inhibitor\" -> 90%",
    "CHAIN: \"Gp2b3A inhibitors\" -> \"are a class of drugs\" -> \"abciximab, eptifibatide, and tirofiban belong to this class\" -> \"prasugrel is a thienopyridine\" -> \"prasugrel does not inhibit Gp2b3A\" -> 85%"
  ],
  "enhanced_information": "Gp2b3A inhibitors are a class of drugs that specifically inhibit the glycoprotein IIb/IIIa receptor on platelets, preventing platelet aggregation. The main examples of Gp2b3A inhibitors include abciximab, eptifibatide, and tirofiban. In contrast, prasugrel is classified as a thienopyridine antiplatelet agent that works through a different mechanism by inhibiting the ADP receptor on platelets, thus it does not belong to the Gp2b3A inhibitor class. Therefore, the correct answer to the question is prasugrel, as it is not a Gp2b3A inhibitor.",
  "analysis": "Gp2b3A inhibitors are a class of antiplatelet drugs that target the glycoprotein IIb/IIIa receptor on platelets, thereby preventing platelet aggregation. The main drugs in this class include abciximab, eptifibatide, and tirofiban. Prasugrel, on the other hand, is a thienopyridine antiplatelet agent that inhibits the ADP receptor on platelets, which is a different mechanism of action. Therefore, prasugrel is not a Gp2b3A inhibitor. Based on standard pharmacological knowledge, the correct answer is that prasugrel is not a Gp2b3A inhibitor.",
  "answer": "opd",
  "confidence": 100.0,
  "chain_coverage": {
    "success_counts": [
      4,
      3,
      5
    ],
    "coverage_rates": [
      33.33333333333333,
      25.0,
      41.66666666666667
    ],
    "total_successes": 12
  },
  "normal_results": []
}